CLAIMS

1. A solid pharmaceutical composition comprising
    a) 0.5-60 mg ~~GLP-1 agonist~~ semaglutide;
    b) 1-50 mg ~~SGLT2 inhibitor~~ dapagliflozin;
    c) 20-800 mg, such as 50-600 mg, of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC); and
    d) 0.6-30 mg, such as 1-50 mg, lubricant;

    wherein said salt of NAC constitutes at least 90 %(w/w), such as at least 95 %(w/w), of the excipients of the composition.

2. The solid pharmaceutical composition according to ~~any of the preceding claims~~ claim 1, wherein said composition essentially consists of:
    a) ~~a GLP-1 agonist~~ semaglutide;
    b) ~~an SGLT2 inhibitor~~ dapagliflozin:
    c) a salt of NAC; and
    d) at least one lubricant.

3. The solid pharmaceutical composition according to any of the preceding claims, wherein the lubricant is magnesium stearate or glyceryl dibehenate.

4. The solid pharmaceutical composition according to any of the preceding claims, wherein the composition is for oral administration ~~and the composition is solid~~, such as in the form of a tablet.

5. The solid pharmaceutical composition according to any of the preceding claims, wherein said salt of NAC constitutes at least 60 %(w/w), such as at least 75 %(w/w) or at least 80 %(w/w), of the composition.

6. The solid pharmaceutical composition according to any of the preceding claims, wherein the composition~~s~~ comprises 1-10 mg, such as 2-5 mg or 2-3 mg, lubricant ~~(e.g. magnesium stearate)~~ per 100 mg of said salt of NAC.

7. The pharmaceutical composition according to any of the preceding claims, wherein the ~~GLP-1 agonist is semaglutide~~ lubricant is magnesium stearate.

~~8. The pharmaceutical composition according to any of the preceding claims, wherein the SGLT2 inhibitor is selected from the group consisting of: dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, sotagliflozin, ipragliflozin, tofogliflozin, luseogliflozin, bexagliflozin, and remogloflozin.~~

8. The solid pharmaceutical composition according to any of the preceding claims, wherein dapagliflozin is selected from the group consisting of: dapagliflozin propylene glycol solvate hydrate, dapagliflozin citrate (1:1), and dapagliflozin di-L-proline (1:2).

9. The solid pharmaceutical composition according to any of the preceding claims, wherein the salt of NAC is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

10. The solid pharmaceutical composition according to any of the preceding claims, wherein the tablet has a weight of 100-800 mg.

11. ~~The~~ A solid pharmaceutical composition ~~according to any of the preceding claims~~, wherein a dose unit comprises
    a) 1-60 mg semaglutide,
    b) 5-25 mg ~~SGLT2 inhibitor (such as 10 mg~~ dapagliflozin (such as 10 mg) ~~or 25 mg empagliflozin)~~,
    c) 50-600 mg SNAC, and
    d) 1-50 mg lubricant, such as magnesium stearate.

~~12. The pharmaceutical composition according to any of the preceding claims, wherein a dose unit comprises~~
    ~~a) 1-60 mg semaglutide,~~
    ~~b) 5-25 mg SGLT2 inhibitor (such as 10 mg dapagliflozin or 25 mg empagliflozin),~~
    ~~c) 50-400 mg SNAC, and~~
    ~~d) 1-50 mg lubricant, such as magnesium stearate.~~

~~13.~~12. ~~The~~ A solid pharmaceutical composition ~~according to any of the preceding claims~~, wherein a dose unit comprises

a) 1-60 mg semaglutide,

b) 5-25 mg ~~SGLT2 inhibitor (such as 10 mg~~ dapagliflozin~~ or 25 mg empagliflozin)~~,

c) 100-300 mg SNAC, and

d) 1-30 mg ~~lubricant, such as~~ magnesium stearate.

~~14.~~13. A solid pharmaceutical composition according to any of the preceding claims for use in medicine.

~~15.~~14. A solid pharmaceutical composition according to any of claims ~~1-13~~ 1-12 for use in ~~a method of~~ the treatment of diabetes and/or obesity.